Psyros POC platform advanced to design freeze, enabling pilot production and regulatory studies. Q1 2026 saw no sales, EBIT loss of -10.4 MSEK, and strong liquidity post-quarter from an R&D tax credit. Market interest and patent portfolio remain robust.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.